Orbis Research

Orbisresearch.com added latest 280 pages report “OpportunityAnalyzer: Ovarian Cancer-Opportunity Analysis and Forecasts to 2025” in its store.

DALLAS, TEXAS, UNITED STATES, August 29, 2017 /EINPresswire.com/ -- Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death amongst gynecological cancers. Due to the nonspecific nature of disease symptoms, the majority of ovarian cancer patients are diagnosed with advanced-stage disease, at which point the prognosis is poor. Current standard of care therapies focus on debulking surgery and platinum-based chemotherapy, with carboplatin and paclitaxel being the gold standard. The majority of patients respond well to initial first-line therapy and enter into remission, however over 80% of patients will relapse and require multiple lines of therapy.

Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/358335

For many years the ovarian cancer drug market has been fairly stagnant, mainly due to the high use of generics and the lack of successful development of new innovative therapies. However, with the recent approvals of Avastin and the PARP inhibitors Lynparza (olaparib), Rubraca (rucaparib), and Zejula (niraparib), the market is beginning to diversify. New understanding of the heterogeneity and biology of ovarian cancer has led to the active development of new targeted therapies, immuno-oncology (IO) drugs, and next-generation chemotherapies. A greater understanding of the tumor microenvironment is expected to occur over the forecast period, which is anticipated to further drive the successful development of new patient-specific therapies. GlobalData is predicting a total of 9 new entrants to launch over the forecast period from 2015-2025. Competition will be particularly fierce amongst PARP inhibitors as they continue to establish their place in the treatment paradigm of ovarian cancer.

Key Questions Answered
- How will the ovarian cancer market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) change from 2015-2025?
- What are the most promising late-stage pipeline drugs in ovarian cancer?
- How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
- What are the unmet needs in ovarian cancer treatment management?
- What drivers and barriers will affect ovarian cancer therapeutics sales in the 7MM over the forecast period?

Scope
- Overview of ovarian cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline ovarian cancer market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting ovarian cancer therapeutics sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the 7MM ovarian cancer therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM ovarian cancer therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the ovarian cancer therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Buy a report @ http://www.orbisresearch.com/contact/purchase/358335

List of Figures
Figure 1: 7MM Sales from Therapeutic Agents by Region, 2015 and 2025 12
Figure 2: Competitive Assessment of Key Ovarian Cancer Pipeline Products, 2017 15
Figure 3: Selected Types of Ovarian Cancer and Other Closely Related Neoplasms 23
Figure 4: Risk Factors and Symptoms Suggestive of Ovarian Cancer 25
Figure 5: 7MM, Diagnosed Incidence Rate of OC, Cases per 100,000, All Ages, Women, 1998?2007 30
Figure 6: 7MM, Diagnosed Incident Cases of OC, Ages ≥18 Years, N, 2015-2025 36
Figure 7: 7MM, Age-Specific Diagnosed Incident Cases of OC, N (Row %), 2015 38
Figure 8: 7MM, Age-Standardized Diagnosed Incidence of OC, Ages≥18 Years, Cases per 100,000, 2015 39
Figure 9: 7MM, Diagnosed Incident Cases of PPC, Ages ≥18 Years, N, 2015-2025 40
Figure 10: 7MM, Five-Year Diagnosed Prevalent Cases of OC and PPC, Ages ≥18 Years, N, 2015-2025 42
Figure 11: Top-Level Treatment Flow Chart for Ovarian Cancer Patients 48
Figure 12: Clinical Development Program for Avastin in Ovarian Cancer 53
Figure 13: Clinical Development Program for Lynparza in Ovarian Cancer 63
Figure 14: Clinical Development Program for Rubraca in Ovarian Cancer 72
Figure 15: Clinical Devlopment Program for Zejula in Ovarian Cancer 78
Figure 16: Clinical Development Program for Yondelis in Ovarian Cancer 83
Figure 17: Clinical Development Program for Bavencio in Ovarian Cancer 131
Figure 18: Clinical Development Program for Opdivo in Ovarian Cancer 136
Figure 19: Clinical Development Program for Tecentriq in Ovarian Cancer 142
Figure 20: Clinical Development Program for Vigil in Ovarian Cancer 148
Figure 21: Clinical Development Program for Fosbretabulin in Ovarian Cancer 153
Figure 22: Clinical Development Program for Veliparib in Ovarian Cancer 160
Figure 23: Clinical Development Program for Mirvetuximab Soravtansine in Ovarian Cancer 165
Figure 24: Clinical Development Program for Opaxio in Ovarian Cancer 170
Figure 25: Clinical Development Program for Lurbinectedin in Ovarian Cancer 175
Figure 26: Clinical Development Program for Apealea in Ovarian Cancer 180
Figure 27: Clinical Development Program for Cediranib in Ovarian Cancer 192
Figure 28: Competitive Assessment of Key Ovarian Cancer Pipeline Products, 2017 211
Figure 29: Sales for Ovarian Cancer Products by Region, 2015-2025 214

About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Hector Costello
Orbis Research
+1 (214) 884-6817
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.